Acacia Subsidiary Enters into a Settlement Agreement Regarding Pressurized Metered Dose Inhalers

  Acacia Subsidiary Enters into a Settlement Agreement Regarding Pressurized
  Metered Dose Inhalers

Business Wire

NEWPORT BEACH, Calif. -- October 21, 2013

Acacia Research Corporation (NASDAQ:ACTG) announced today that its Accuhale
LLC subsidiary has entered into a settlement agreement regarding pressurized
metered dose inhalers with AstraZeneca LP, AstraZeneca Pharmaceuticals LP,
AstraZeneca Dunkerque Production SCS and AstraZeneca AB. The agreement
resolves litigation that was pending in the United States District Court for
the Eastern District of Texas.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation’s subsidiaries partner with inventors and patent
owners, license the patents to corporate users, and share the revenue.

Information about Acacia Research Corporation and its subsidiaries is
available at and www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This news release may contain forward-looking statements within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act
of 1995. Such statements are based upon our current expectations and speak
only as of the date hereof. Our actual results may differ materially and
adversely from those expressed in any forward-looking statements as a result
of various factors and uncertainties, including the recent economic slowdown
affecting technology companies, our ability to successfully develop products,
rapid technological change in our markets, changes in demand for our future
products, legislative, regulatory and competitive developments and general
economic conditions. Our Annual Report on Form 10-K, recent and forthcoming
Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A,
and other SEC filings discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We
undertake no obligation to revise or update publicly any forward-looking
statements for any reason.

Contact:

Acacia Research Corporation
Rob Stewart, Investor Relations
Tel 949-480-8300
Fax 949-480-8301
or
Media Contact:
SpecOps Communications
Adam Handelsman, President & Founder
Tel 212-518-7721
adam@specopscomm.com
 
Press spacebar to pause and continue. Press esc to stop.